

Update from WG3

WG3 Leader – Prof. Carlo Catapano (CH)

WG3 Vice-leader – Prof. Ulf Kahlert (DE)

WG3 update

Objective: *Define standards for in vitro/in vivo testing and preclinical/translational studies of nanomedicines for oncological applications.*

GP goals: *GAPG1-4, GAPG6 and GAPG8*

Planned initiatives:

- WG3 meeting (Bellinzona, CH)
- WG3 workshop (Magdeburg, DE)

WG3 update

WG3 objectives: *Define standards for preclinical testing of nanomedicines in oncology*

WG3 meeting

- **Participants:** 5-10 people; small working group
- **Aims and scope:** explore the state-of-the-art and propose guidelines and roadmaps for preclinical and translational studies.
- **Output:** Prepare and draft WG3 deliverables, related milestones, position papers.
- **Organizers:** Prof. Carlo Catapano & Prof. Ulf Kahlert (WG3 leader & co-leader).
- **Dates:** March 3-4, 2022 (2 days)
- **Location:** Institute of Oncology Research (IOR), Bellinzona (CH).



Advancing cancer nano-medicine to the clinics: hypes, hopes and hurdles



Date: 16/17 June (Thu/Fri)



Location: Research Campus *STIMULATE*
Solution Centre for Image Guided Local Therapies



Accommodation and evening dinner : Old city center

Agenda:
... in progress

1. Disease models – state of the art for physiological relevant and repeatable testing
2. Nanocarriers – current technologies and benchmarks
3. Nanomedicine – the viewpoint of the clinicians
4. Working meeting – grant strategy and position paper

Participants:
... in progress

N=5 international invitations:

Models	SUI	M	
Particles	POR	M	
Particles	NL	M	
Nano-Bio-Devices	NL	F	
Models	NL	?	industry

N=5 national opinion makers

N= 6 local clinical decision makers

Optional (for internationals): visit UNESCO word heritage sites of

BAUHAUS Dessau



Wittenberg
(Martin Luther
reformation)

